Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 12Neoplasms 8Lymphoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Solid Tumors 2Lymphoma, Non-Hodgkin 2Thromboembolism 1Recurrence 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Carcinoma 1Breast Neoplasms 1Advanced Cancer 1Adult Solid Neoplasm 1

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × Ketoconazole × Clear all
NCT00708591 2014-01-17

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

University of Chicago

Phase 1 Completed
57 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡